Recent Experience with DCIS Score
The DCIS score can help patients and physicians work together to determine whether or not chemotherapy will be beneficial, based on a personal assay taken at the time of surgery. That tumor assay is then analyzed, and a recurrence score, or the likelihood of recurrence, is assigned. Here, Rick Baehner, MD and Senior Director of Pathology at Genomic Health, Inc. gives a recent example of a patient with an experience using the DCIS score.
Genomic Health is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. The company's lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).
SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS
http://www.youtube.com/user/drjayharness
VISIT BREASTCANCERANSWERS.com FOR INFORMATIVE VIDEOS
http://www.breastcanceranswers.....com/video-categorie
SUBMIT A QUESTION
http://www.breastcanceranswers.com/ask
DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR
http://www.breastcanceranswers.....com/what-breast-can
CONNECT WITH US!
Google+: http://bit.ly/16nhEnr
Facebook: https://www.facebook.com/BreastCancerAnswers
Twitter: https://twitter.com/BreastCancerDr
______
Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
-
Category
No comments found